Surma, Stanisław
Sahebkar, Amirhossein
Banach, Maciej
Article History
Accepted: 22 December 2023
First Online: 2 January 2024
Change Date: 22 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11883-024-01189-4
Declarations
:
: S.S.—honoraria from Sandoz/Novartis; Pro.Med.; A.S.—no conflict of interest; M.B.—speakers bureau: Amgen, Daiichi Sankyo, KRKA, Pfizer, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Pfizer, Sanofi-Aventis, Teva, and Zentiva; consultant to Adamed, Amgen, Daiichi Sankyo, Esperion, MSD, NewAmsterdam, Novartis, Novo-Nordisk, and Sanofi-Aventis; Grants from Amgen, Daiichi Sankyo, Viatris, and Sanofi; CMO at the Nomi Biotech Corporation and Dairy Biotechnologies. In addition, M.B. reports the following: President of the International Lipid Expert Panel (ILEP), Secretary of the European Atherosclerosis Society (EAS), and President of the Polish Lipid Association (PoLA).
: This article does not contain any studies with human or animal subjects performed by any of the authors.